|
Part I Directed Evolution |
|
|
1 | (132) |
|
1 Continuous Evolution of Proteins In Vivo |
|
|
3 | (26) |
|
|
|
|
|
3 | (2) |
|
1.2 Challenges in Achieving In Vivo Continuous Evolution |
|
|
5 | (5) |
|
1.3 Phage-Assisted Continuous Evolution (PACE) |
|
|
10 | (3) |
|
1.4 Systems That Allow In Vivo Continuous Directed Evolution |
|
|
13 | (9) |
|
1.4.1 Targeted Mutagenesis in E. coli with Error-Prone DNA Polymerase |
|
|
13 | (3) |
|
1.4.2 Yeast Systems That Do Not Use Engineered DNA Polymerases for Mutagenesis |
|
|
16 | (2) |
|
1.4.3 Somatic Hypermutation as a Means for Targeted Mutagenesis of GOIs |
|
|
18 | (2) |
|
1.4.4 Orthogonal DNA Replication (OrthoRep) |
|
|
20 | (2) |
|
|
22 | (7) |
|
|
22 | (7) |
|
2 In Vivo Biosensors for Directed Protein Evolution |
|
|
29 | (28) |
|
|
|
|
29 | (3) |
|
2.2 Nucleic Acid-Based In Vivo Biosensors for Directed Protein Evolution |
|
|
32 | (5) |
|
2.2.1 RNA-Type Biosensors |
|
|
32 | (3) |
|
2.2.2 DNA-Type Biosensors |
|
|
35 | (2) |
|
2.3 Protein-Based In Vivo Biosensors for Directed Protein Evolution |
|
|
37 | (7) |
|
2.3.1 Transcription Factor-Type Biosensors |
|
|
37 | (4) |
|
2.3.2 Enzyme-Type Biosensors |
|
|
41 | (3) |
|
2.4 Characteristics of Biosensors for In Vivo Directed Protein Evolution |
|
|
44 | (1) |
|
2.5 Conclusions and Future Perspectives |
|
|
45 | (12) |
|
|
46 | (1) |
|
|
46 | (11) |
|
3 High-Throughput Mass Spectrometry Complements Protein Engineering |
|
|
57 | (24) |
|
|
|
|
|
|
|
57 | (2) |
|
3.2 Procedures and Instrumentation for MS-Based Protein Assays |
|
|
59 | (3) |
|
3.3 Technology Advances Focusing on Throughput Improvement |
|
|
62 | (1) |
|
3.4 Applications of MS-Based Protein Assays: Summary |
|
|
63 | (5) |
|
3.4.1 Applications of MS-Based Assays: Protein Analysis |
|
|
64 | (2) |
|
3.4.2 Applications of MS-Based Assays: Protein Engineering |
|
|
66 | (2) |
|
3.5 Conclusions and Perspectives |
|
|
68 | (13) |
|
|
68 | (1) |
|
|
69 | (12) |
|
4 Recent Advances in Cell Surface Display Technologies for Directed Protein Evolution |
|
|
81 | (13) |
|
Maryam Raeeszadeh-Sarmazdeh |
|
|
|
|
81 | (5) |
|
|
81 | (2) |
|
4.1.2 Bacterial Display Systems |
|
|
83 | (1) |
|
4.1.3 Yeast Surface Display |
|
|
84 | (1) |
|
|
85 | (1) |
|
4.2 Selection Methods and Strategies |
|
|
86 | (3) |
|
4.2.1 High-Throughput Cell Screening |
|
|
86 | (1) |
|
|
86 | (1) |
|
|
86 | (1) |
|
|
87 | (1) |
|
4.2.2 Selection Strategies |
|
|
88 | (1) |
|
4.2.2.1 Competitive Selection (Counter Selection) |
|
|
88 | (1) |
|
4.2.2.2 Negative/Positive Selection |
|
|
89 | (1) |
|
4.3 Modifications of Cell Surface Display Systems |
|
|
89 | (4) |
|
4.3.1 Modification of YSD for Enzyme Engineering |
|
|
89 | (2) |
|
4.3.2 Yeast Co-display System |
|
|
91 | (1) |
|
4.3.3 Surface Display of Multiple Proteins |
|
|
91 | (2) |
|
4.4 Recent Advances to Expand Cell-Display Directed Evolution Techniques |
|
|
93 | (1) |
|
4.4.1 nSCALE (Microcapillary Single-Cell Analysis and Laser Extraction) |
|
|
93 | (1) |
|
4.4.2 Combining Cell Surface Display and Next-Generation Sequencing |
|
|
94 | (1) |
|
4 A3 PACE (Phage-Assisted Continuous Evolution) |
|
|
94 | (11) |
|
4.5 Conclusion and Outlook |
|
|
96 | (9) |
|
|
97 | (8) |
|
5 Iterative Saturation Mutagenesis for Semi-rational Enzyme Design |
|
|
105 | (28) |
|
|
|
|
|
105 | (3) |
|
5.2 Recent Methodology Developments in ISM-Based Directed Evolution |
|
|
108 | (12) |
|
5.2.1 Choosing Reduced Amino Acid Alphabets Properly |
|
|
109 | (1) |
|
5.2.1.1 Limonene Epoxide Hydrolase as the Catalyst in Hydrolytic Desymmetrization |
|
|
109 | (1) |
|
5.2.1.2 Alcohol Dehydrogenase TbSADH as the Catalyst in Asymmetric Transformation of Difficult-to-Reduce Ketones |
|
|
110 | (2) |
|
5.2.1.3 P450-BM3 as the Chemo- and Stereoselective Catalyst in a Whole-Cell Cascade Sequence |
|
|
112 | (3) |
|
5.2.1.4 Multi-parameter Evolution Aided by Mutability Landscaping |
|
|
115 | (2) |
|
5.2.2 Further Methodology Developments of CAST/ISM |
|
|
117 | (1) |
|
5.2.2.1 Advances Based on Novel Molecular Biological Techniques and Computational Methods |
|
|
117 | (1) |
|
5.2.2.2 Advances Based on Solid-Phase Chemical Synthesis of SM Libraries |
|
|
118 | (2) |
|
5.3 B-FIT as an ISM Method for Enhancing Protein Thermostability |
|
|
120 | (1) |
|
5.4 Learning from CAST/ISM-Based Directed Evolution |
|
|
121 | (1) |
|
5.5 Conclusions and Perspectives |
|
|
121 | (12) |
|
|
124 | (1) |
|
|
124 | (9) |
|
Part II Rational and Semi-Rational Design |
|
|
133 | (110) |
|
6 Data-driven Protein Engineering |
|
|
135 | (18) |
|
|
|
|
|
135 | (1) |
|
6.2 The Data Revolution in Biology |
|
|
136 | (2) |
|
6.3 Statistical Representations of Protein Sequence, Structure, and Function |
|
|
138 | (3) |
|
6.3.1 Representing Protein Sequences |
|
|
138 | (2) |
|
6.3.2 Representing Protein Structures |
|
|
140 | (1) |
|
6.4 Learning the Sequence-Function Mapping from Data |
|
|
141 | (4) |
|
6.4.1 Supervised Learning (Regression/Classification) |
|
|
141 | (3) |
|
6.4.2 ~ Unsupervised/Semisupervised Learning |
|
|
144 | (1) |
|
6.5 Applying Statistical Models to Engineer Proteins |
|
|
145 | (2) |
|
6.6 Conclusions and Future Outlook |
|
|
147 | (6) |
|
|
148 | (5) |
|
7 Protein Engineering by Efficient Sequence Space Exploration Through Combination of Directed Evolution and Computational Design Methodologies |
|
|
153 | (24) |
|
|
|
|
|
|
153 | (1) |
|
7.2 Protein Engineering Strategies |
|
|
154 | (17) |
|
7.2.1 Computer-Aided Rational Design |
|
|
155 | (1) |
|
|
155 | (2) |
|
|
157 | (1) |
|
|
158 | (1) |
|
|
159 | (1) |
|
|
160 | (1) |
|
7.2.2 Knowledge Based Directed Evolution |
|
|
161 | (1) |
|
7.2.2.1 Iterative Saturation Mutagenesis (ISM) |
|
|
161 | (1) |
|
7.2.2.2 Mutagenic Organized Recombination Process by Homologous In Vivo Grouping (MORPHING) |
|
|
161 | (1) |
|
7.2.2.3 Knowledge Gaining Directed Evolution (KnowVolution) |
|
|
162 | (9) |
|
7.3 Conclusions and Future Perspectives |
|
|
171 | (6) |
|
|
171 | (1) |
|
|
171 | (6) |
|
8 Engineering Artificial Metalloenzymes |
|
|
177 | (30) |
|
|
|
|
|
|
|
177 | (1) |
|
|
177 | (11) |
|
8.2.1 Rational Design of Metalloenzymes Using De Novo Designed Scaffolds |
|
|
177 | (2) |
|
8.2.2 Rational Design of Metalloenzymes Using Native Scaffolds |
|
|
179 | (1) |
|
8.2.2.1 Redesign of Native Proteins |
|
|
179 | (2) |
|
8.2.2.2 Cofactor Replacement in Native Proteins |
|
|
181 | (3) |
|
8.2.2.3 Covalent Anchoring in Native Protein |
|
|
184 | (3) |
|
8.2.2.4 Supramolecular Anchoring in Native Protein |
|
|
187 | (1) |
|
8.3 Engineering Artificial Metalloenzyme by Directed Evolution in Combination with Rational Design |
|
|
188 | (12) |
|
8.3.1 Directed Evolution of Metalloenzymes Using De Novo Designed Scaffolds |
|
|
188 | (1) |
|
8.3.2 Directed Evolution of Metalloenzymes Using Native Scaffolds |
|
|
189 | (1) |
|
8.3.2.1 Cofactor Replacement in Native Proteins |
|
|
189 | (3) |
|
8.3.2.2 Covalent Anchoring in Native Protein |
|
|
192 | (2) |
|
8.3.2.3 Non-covalent Anchoring in Native Proteins |
|
|
194 | (6) |
|
|
200 | (7) |
|
|
201 | (1) |
|
|
201 | (6) |
|
9 Engineered Cytochromes P450 for Biocatalysis |
|
|
207 | (36) |
|
|
|
9.1 Cytochrome P450 Monooxygenases |
|
|
207 | (3) |
|
9.2 Engineered Bacterial P450s for Biocatalytic Applications |
|
|
210 | (17) |
|
9.2.1 Oxyfunctionalization of Small Organic Substrates |
|
|
211 | (9) |
|
9.2.2 Late-Stage Functionalization of Natural Products |
|
|
220 | (4) |
|
9.2.3 Synthesis of Drug Metabolites |
|
|
224 | (3) |
|
9.3 High-throughput Methods for Screening Engineered P450s |
|
|
227 | (2) |
|
9.4 Engineering of Hybrid P450 Systems |
|
|
229 | (1) |
|
9.5 Engineered P450s with Improved Thermostability and Solubility |
|
|
230 | (1) |
|
|
231 | (12) |
|
|
232 | (1) |
|
|
232 | (11) |
|
Part III Applications in Industrial Biotechnology |
|
|
243 | (134) |
|
10 Protein Engineering Using Unnatural Amino Acids |
|
|
245 | (20) |
|
|
|
|
|
245 | (1) |
|
10.2 Methods for Unnatural Amino Acid Incorporation |
|
|
246 | (1) |
|
10.3 Applications of Unnatural Amino Acids in Protein Engineering |
|
|
247 | (9) |
|
10.3.1 Enhancing Stability |
|
|
248 | (1) |
|
10.3.2 Mechanistic Study Using Spectroscopic Methods |
|
|
248 | (2) |
|
10.3.3 Tuning Catalytic Activity |
|
|
250 | (2) |
|
10.3.4 Tuning Selectivity |
|
|
252 | (1) |
|
|
252 | (3) |
|
10.3.6 Protein Engineering Toward a Synthetic Life |
|
|
255 | (1) |
|
|
256 | (2) |
|
|
258 | (7) |
|
|
258 | (7) |
|
11 Application of Engineered Biocatalysts for the Synthesis of Active Pharmaceutical Ingredients (APIs) |
|
|
265 | (30) |
|
|
|
|
|
265 | (17) |
|
|
266 | (1) |
|
|
266 | (1) |
|
|
267 | (1) |
|
|
267 | (4) |
|
11.1.2.2 Amino Acid Dehydrogenases |
|
|
271 | (1) |
|
11.1.2.3 Cytochrome P450 Monoxygenases |
|
|
272 | (1) |
|
11.1.2.4 Baeyer-Villiger Monoxygenases |
|
|
273 | (1) |
|
|
274 | (2) |
|
|
276 | (1) |
|
11.1.2.7 Imine Reductases |
|
|
276 | (2) |
|
|
278 | (1) |
|
|
278 | (1) |
|
|
278 | (1) |
|
|
279 | (1) |
|
|
279 | (1) |
|
11.1.5.2 Haloalkane Dehalogenase |
|
|
279 | (2) |
|
11.1.6 Multi-enzyme Cascade |
|
|
281 | (1) |
|
|
282 | (13) |
|
|
287 | (8) |
|
12 Directing Evolution of the Fungal Ligninolytic Secretome |
|
|
295 | (22) |
|
|
|
12.1 The Fungal Ligninolytic Secretome |
|
|
295 | (2) |
|
12.2 Functional Expression in Yeast |
|
|
297 | (5) |
|
12.2.1 The Evolution of Signal Peptides |
|
|
297 | (3) |
|
12.2.2 Secretion Mutations in Mature Protein |
|
|
300 | (1) |
|
12.2.3 The Importance of Codon Usage |
|
|
301 | (1) |
|
12.3 Yeast as a Tool-Box in the Generation of DNA Diversity |
|
|
302 | (3) |
|
12.4 Bringing Together Evolutionary Strategies and Computational Tools |
|
|
305 | (1) |
|
12.5 High-Throughput Screening (HTS) Assays for Ligninase Evolution |
|
|
306 | (3) |
|
12.6 Conclusions and Outlook |
|
|
309 | (8) |
|
|
309 | (1) |
|
|
310 | (7) |
|
13 Engineering Antibody-Based Therapeutics: Progress and Opportunities |
|
|
317 | (36) |
|
|
|
|
317 | (1) |
|
|
318 | (4) |
|
13.2.1 Human IgGl Structure |
|
|
318 | (1) |
|
13.2.2 Antibody-Drug Conjugates |
|
|
319 | (1) |
|
13.2.3 Bispecific Antibodies |
|
|
320 | (1) |
|
13.2.4 Single Domain Antibodies |
|
|
321 | (1) |
|
13.2.5 Chimeric Antigen Receptors |
|
|
321 | (1) |
|
|
322 | (6) |
|
13.3.1 Antibody Target Identification |
|
|
322 | (1) |
|
13.3.1.1 Cancer and Autoimmune Disease Targets |
|
|
323 | (1) |
|
13.3.1.2 Infectious Disease Targets |
|
|
323 | (1) |
|
13.3.2 Screening for Target-Binding Antibodies |
|
|
324 | (1) |
|
13.3.2.1 Synthetic Library Derived Antibodies |
|
|
324 | (1) |
|
13.3.2.2 Host-Derived Antibodies |
|
|
325 | (1) |
|
|
325 | (1) |
|
13.3.2.4 Pairing the Light and Heavy Variable Regions |
|
|
326 | (1) |
|
|
327 | (1) |
|
13.3.2.6 Hybrid Approaches to Antibody Discovery |
|
|
328 | (1) |
|
13.4 Therapeutic Optimization of Antibodies |
|
|
328 | (8) |
|
|
328 | (1) |
|
13.4.1.1 Antibody Half-Life Extension |
|
|
329 | (2) |
|
13.4.1.2 Antibody Half-Life Reduction |
|
|
331 | (1) |
|
13.4.1.3 Effect of Half-Life Modification on Effector Functions |
|
|
331 | (1) |
|
13.4.2 Effector Functions |
|
|
331 | (1) |
|
13.4.2.1 Effector Function Considerations for Cancer Therapeutics |
|
|
332 | (1) |
|
13.4.2.2 Effector Function Considerations for Infectious Disease Prophylaxis and Therapy |
|
|
333 | (1) |
|
13.4.2.3 Effector Function Considerations for Treating Autoimmune Disease |
|
|
334 | (1) |
|
13.4.2.4 Approaches to Engineering the Effector Functions of the IgGl Fc |
|
|
334 | (1) |
|
13.4.3 Tissue Localization |
|
|
335 | (1) |
|
|
335 | (1) |
|
13.4.4.1 Reducing T-Cell Recognition |
|
|
336 | (1) |
|
13.4.4.2 Reducing Aggregation |
|
|
336 | (1) |
|
13.5 Manufacturability of Antibodies |
|
|
336 | (3) |
|
13.5.1 Increasing Antibody Yield |
|
|
337 | (1) |
|
|
337 | (1) |
|
13.5.1.2 Signal Peptide Optimization |
|
|
337 | (1) |
|
13.5.1.3 Expression Optimization |
|
|
338 | (1) |
|
13.5.2 Alternative Production Methods |
|
|
338 | (1) |
|
|
339 | (14) |
|
|
339 | (1) |
|
|
339 | (14) |
|
14 Programming Novel Cancer Therapeutics: Design Principles for Chimeric Antigen Receptors |
|
|
353 | (24) |
|
|
|
|
353 | (1) |
|
14.2 Metrics to Evaluate CAR-T Cell Function |
|
|
354 | (2) |
|
14.3 Antigen-Recognition Domain |
|
|
356 | (4) |
|
14.3.1 Tuning the Antigen-Recognition Domain to Manage Toxicity |
|
|
356 | (1) |
|
14.3.2 Incorporation of Multiple Antigen-Recognition Domains to Engineer "Smarter" CARs |
|
|
356 | (3) |
|
14.3.3 Novel Antigen-Recognition Domains to Enhance CAR Modularity |
|
|
359 | (1) |
|
14.3.4 Engineering CARs that Target Soluble Factors |
|
|
360 | (1) |
|
14.4 Extracellular Spacer |
|
|
360 | (2) |
|
14.5 Transmembrane Domain |
|
|
362 | (1) |
|
|
362 | (4) |
|
14.6.1 First-and Second-Generation CARs |
|
|
362 | (1) |
|
14.6.2 Combinatorial Co-stimulation |
|
|
363 | (1) |
|
14.6.3 Other Co-stimulatory Domains: ICOS, OX40, TLR2 |
|
|
364 | (1) |
|
14.6.4 Additional Considerations for CAR Signaling Domains |
|
|
364 | (2) |
|
14.7 High-Throughput CAR Engineering |
|
|
366 | (1) |
|
14.8 Novel Receptor Modalities |
|
|
367 | (10) |
|
|
369 | (8) |
|
Part IV Applications in Medical Biotechnology |
|
|
377 | (17) |
|
15 Development of Novel Cellular Imaging Tools Using Protein Engineering |
|
|
379 | (15) |
|
|
|
|
|
|
|
379 | (1) |
|
15.2 Cellular Imaging Tools Developed by Protein Engineering |
|
|
380 | (6) |
|
15.2.1 Fluorescent Proteins |
|
|
380 | (1) |
|
15.2.1.1 The FP Color Palette |
|
|
380 | (1) |
|
15.2.1.2 Photocontrollable Fluorescent Proteins |
|
|
381 | (2) |
|
15.2.1.3 Other Engineered Fluorescent Proteins |
|
|
383 | (1) |
|
15.2.2 Antibodies and Protein Scaffolds |
|
|
383 | (1) |
|
|
383 | (1) |
|
15.2.2.2 Antibody-Like Protein Scaffolds |
|
|
384 | (1) |
|
15.2.2.3 Directed Evolution |
|
|
384 | (1) |
|
15.2.3 Genetically Encoded Non-fluorescent Protein Tags |
|
|
385 | (1) |
|
15.3 Application in Cellular Imaging |
|
|
386 | (7) |
|
15.3.1 Cell Biology Applications |
|
|
386 | (1) |
|
|
386 | (1) |
|
|
387 | (3) |
|
15.3.2 Application in Diagnostics and Medicine |
|
|
390 | (1) |
|
|
390 | (2) |
|
15.3.2.2 Screening for Drugs |
|
|
392 | (1) |
|
15.4 Conclusion and Perspectives |
|
|
393 | (1) |
References |
|
394 | (9) |
Index |
|
403 | |